Financials
Financial year 2025
APOTHEEK VERLINDEN from Antwerpen, company number BE0429633487, closed financial year 2025 with a result of € 45,540 after tax. For that financial year APOTHEEK VERLINDEN recorded a gross margin of € 470,645 and equity of € 666,668. Compared with financial year 2024, the result moved from € 79,663 to € 45,540. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.
€ 666,668
▲ 7% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 45,540
▼ 43% vs 2024
Profit after tax over the fiscal year.
€ 61,881
▼ 42% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 489,668.
People and assets in 2025
6.3
▲ 0.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 372,536
▼ 3% vs 2024
€ 59,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 6,709
▲ 39% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 195,540
▼ 4% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 38,451
▼ 34% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 405,353 | € 317,971 | € 518,208 | € 470,645 | ▼ 9% |
| Profit after taxes | € 4,538 | € -144,316 | € 79,663 | € 45,540 | ▼ 43% |
| Equity | € 685,781 | € 541,465 | € 621,128 | € 666,668 | ▲ 7% |
| Total debts | € 375,690 | € 313,895 | € 262,514 | € 243,916 | ▼ 7% |
| Cash | € 306,652 | € 116,540 | € 106,958 | € 61,881 | ▼ 42% |
| Land & buildings | - | € 14,051 | € 13,683 | € 41,212 | ▲ 201% |
| Retained profit | € 508,781 | € 364,465 | € 444,128 | € 489,668 | ▲ 10% |
| Bank debt | € 69,522 | € 0 | € 0 | € 0 | |
| Balance sheet total | € 1,061,471 | € 855,360 | € 883,642 | € 910,584 | ▲ 3% |
| Employees (FTE) | 5.5 | 6.4 | 5.6 | 6.3 | ▲ 0.7 |
Key figures of APOTHEEK VERLINDEN, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to APOTHEEK VERLINDEN?
What happened at APOTHEEK VERLINDEN in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 45,540 (▼ 43% vs 2024). Source: NBB ↗
- Antwerp Pharmacies BV became a director. NBB
- Jeff Roskams Consulting bv became a director. NBB
- New establishment in Antwerpen. KBO
- New establishment in Stabroek. KBO
- Start of the company according to the CBE. KBO
In short
From € 4,538 profit in 2022 to € 45,540 profit in 2025.
Paid € 8,493 in corporate taxes since 2022.
Best year ever: 2024, with € 79,663 profit.
On average € 74,700 of value added per employee in 2025.
A new publication or filing at APOTHEEK VERLINDEN? We notify you, reason included.
Follow APOTHEEK VERLINDENDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of ANTWERP PHARMACIES comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
APOTHEEK VERLINDENBehind APOTHEEK VERLINDEN are Antwerp Pharmacies BV and Jeff Roskams Consulting bv. The shares are held by ANTWERP PHARMACIES (100%).
Directors
According to the 2025 annual accounts
Managing director · represented by Joris Mees
Also active at: INTERNATIONALE APOTHEEK, APOTHEEK R. KROLS b.v.b.a., APOTHEEK VAN DEUN, APOTHEEK SUYKERBUYK, APOTHEEK DIRK VAN HERCK, Farmajes, APOTHEEK PALEIS, EUROPA APOTHEEK
since 2023
Director · represented by Jeff Roskams
Also active at: INTERNATIONALE APOTHEEK, ANTWERP PHARMACIES
since 2023
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Putsebaan 24
2040 Antwerpen
Dorpsstraat 158
2940 Stabroek
Active since 10 December 1986
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0429.633.487
- VAT number
- BE 0429.633.487
- Registered office
- Putsebaan 24, 2040 Antwerpen
- Names & denominations
- APOTHEEK VERLINDEN
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 20 October 1986
- Peppol
- Active · Active since 23 Oct 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers